Role of Histone deacetylase 3 (HDAC3) in intestinal epithelial cell homeostasis and tumorigenesis

组蛋白脱乙酰酶 3 (HDAC3) 在肠上皮细胞稳态和肿瘤发生中的作用

• 批准号: FT0992234
• 负责人: Prof John Mariadason
• 金额: $ 48.96万
• 依托单位: Ludwig Institute for Cancer Research Ltd
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-07-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT0992234
• 关键词: Role; Histone; deacetylase; HDAC3; intestinal

Colon cancer is the most common cancer that affects men and women in Australia. Annually, in Victoria alone, more than 3400 people are diagnosed with colon cancer. Colon cancer arises through the accumulation of mutations in key genes over time. Identification of cancer causing genes provides the basis for the design of new cancer therapies. We recently identified a gene called Histone deacetylase 3 (HDAC3) as potentially involved in promoting colon cancer. The current proposal will now extend and validate this finding in mice. Importantly, drugs which inhibit HDAC3 have recently been developed for the treatment of cutaneous T-cell lymphoma. Defining the role HDAC3 plays in colon cancer will justify testing these drugs in colon cancer patients.

结肠癌是澳大利亚男性和女性中最常见的癌症。每年，仅在维多利亚州，就有超过3400人被诊断患有结肠癌。随着时间的推移，关键基因突变的积累导致了结肠癌的发生。致癌基因的鉴定为设计新的癌症治疗方法提供了基础。我们最近发现了一种叫做组蛋白去乙酰化酶3 （HDAC3）的基因，它可能与结肠癌的发生有关。目前的提议将在老鼠身上扩展和验证这一发现。重要的是，抑制HDAC3的药物最近被开发用于治疗皮肤t细胞淋巴瘤。确定HDAC3在结肠癌中的作用将证明在结肠癌患者身上测试这些药物是合理的。